Wyplay and Alpha Networks to Offer End-to-End Solution for Digital TV Operators
Wyplay, a creator of software solutions for leading pay TV operators, and Alpha Networks, one of the most innovative companies for CMS and SMS backend software, have decided to join their forces and bring into the market their innovative products, Frog and Tucano, as one end-to-end software solution for TV operators.
What will be the added value of this turnkey solution? A comprehensive suite to manage the content, subscribers and payments, integrated with an open source customizable middleware ready to be deployed.
Wyplay and Alpha Networks strongly believe that this partnership will bring an answer to the operator’s main challenges:
- DRM/CAS integration on affordable STB hardware
- EPG management
- Subscription and payment with bank cards
- Multiscreen/convergent approach
Fully based on API exchanges, the solution will provide a modern and customizable user experience pre-integrated on a range of set-top box hardware platforms, thanks to the Frog open source code base. All Frog licensees will have access to Tucano backend functionalities without any extra integration. A first demonstration of the functionalities of this turnkey solution will be presented to the market during CES®, January 6-9 2016, at the Venetian Hotel, San Polo 3401.
“This partnership is really exciting for Alpha Networks. We strongly believe in partnership between an open backend solution and client’s middleware. Today, only some middleware companies have really understood the new market challenges; Tier 2 operators and media companies want an end-to-end solution and no more only a best of breed approach that costs millions of euros and years to be deployed. Wyplay, who is a recognized leader in client technologies, is one of the few innovative companies that have understood this reality. It’s definitely one of the best companies to demonstrate the added value of Tucano backend,” said Guillaume Devezeaux, CTO of Alpha Networks. “We strongly believe that the Frog community will generate lots of new ideas to make Tucano more successful”.
“Alpha Networks’ Tucano is a great complement to our Frog Turnkey product” said Dominique Féral, Wyplay CMO “As a managed cloud-hosted solution combining subscriber management, content management and payments, it significantly reduces the time it takes for an operator to migrate from “plain” digital TV broadcast services or to launch from scratch an hybrid offer leveraging the significant RoI and modern user experience advantages afforded by Frog Turnkey on entry- and mid-level STB hardware.”
In addition, Alpha Networks is becoming a Frog by Wyplay Licensee, thus joining an ecosystem of more than 110 companies across the entire digital TV technology value chain, including chipset vendors, device manufacturers, independent software vendors, software development/integration services providers and operators. The Frog by Wyplay solution gives partners access to the complete source code and all the components to build TV operator products.
# # #
Independent and internationally recognized, Wyplay develops open, modular and innovative software solutions for IPTV, cable, satellite and terrestrial TV operators and broadcasters around the world. Wyplay’s technology enables operators to select, configure, and deploy solutions easily from the richest list of preconfigured functionality available in a modular online TV solution, including an electronic program guide; video recorder; multiscreen and multiroom connectivity, an application store; and more. Wyplay’s professional services team creates user experiences that exactly match and complement an operator or broadcaster’s product and market strategies. Wyplay is now a strategic partner for such leading brands as SFR, Vodafone, Belgacom Proximus, Canal+ and Sky Italia.
About Alpha Networks
Alpha Networks is an innovative software company, specialized in backend software for Media Companies, IPTV and OTT operators. Alpha Networks enables IPTV, Multiscreen and OTT services by providing its comprehensive SMS/CMS software suite pre-integrated with a range of middleware’s and consumer access portals. The Alpha Networks software allows integration with video infrastructure and has been already successfully deployed in worldwide projects that include BeIN Sports, Mobistar (Orange Belgium), Liquid Telecom and many others.
Alpha Networks is going to launch on the 1st of January 2016 its new product named Tucano, a software solution to manage customers’ video content through a simple API interface.
PR Contact for Wyplay
Julie Geret, Phone: +33 621 047 705
Head of Communications
PR Contact for Alpha Networks
Guillaume Devezeaux, Phone: + 32 487 574 302
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19 | Pressemelding
Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom